Atara Biotherapeutics, Inc. (ATRA): restructuring charge — Atara Biotherapeutics cuts ~29% of workforce, retains ~15 employees

Atara Biotherapeutics, Inc.

Workforce reduction impacts about 29% of current employees; expects to complete by January 2026.
Approximately $1.3 million in severance and related benefits anticipated.
Roughly 50% of charges are salary continuation and 60-day notice wages under California WARN Act.
Company retains about 15 employees for strategic priorities.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Atara Biotherapeutics, Inc. announced a restructuring with charges of $1.3 million (approximately 29% of its current employees).

Type: restructuring
Charge: $1.3 million
Headcount: approximately 29% of its current employees

Exact text from the filing

to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by January 2026. The Company expects to recognize approximately $1.3 million for severance and related benefits for employees laid off under the reduction in force. Approximately fifty percent of these charges are salary continuation payments and wages

View on SEC.gov

Browse all restructurings & charges →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-232117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.